Literature DB >> 11195788

Protein kinase C is involved in cardioprotective effects of ischemic preconditioning on infarct size and ventricular arrhythmia in rats in vivo.

K Matsumura1, S Komori, M Takusagawa, M Osada, F Tanabe, M Itoh, K Tamura.   

Abstract

Protein kinase C (PKC) has been known to play an important role in ischemic preconditioning (IP). This study was designed to examine whether the translocation of PKC is associated with the cardioprotective effects of IP in vivo on infarct size and ventricular arrhythmias in a rat model. Using anesthetized rats, heart rate, systolic blood pressure, infarct size and ventricular arrhythmias during 45 min of coronary occlusion were measured. PKC activity was assayed in both the cytosolic and cell membrane fraction. Brief 3-min periods ofischemia followed by 10 min ofreperfusion were used to precondition the myocardium. Calphostin C was used to inhibit PKC. Infarct size was significantly reduced by IP (68.1 (2.5)%, mean (S.E.) vs. 45.2 (3.4)%, p < 0.01). The reduction in infarct size by IP was abolished by pretreatment with calphostin C. The total number of ventricular premature complex (VPC) during 45 min of coronary occlusion was reduced by IP (1474 (169) beats/45 min vs. 256 (82) beats/45 min, p < 0.05). The reduction the total number of VPC induced by IP was abolished by the administration of calphostin C before the episode of brief ischemia. The same tendency was observed in the duration of ventricular tachycardia and the incidence of ventricular fibrillation. PKC activity in the cell membrane fraction transiently increased immediately after IP (100 vs. 142%, p < 0.01) and returned to baseline 15 min after IP. Pretreatment with calphostin C prevented the translocation of PKC. The translocation of PKC plays an important role in the cardioprotective effect of IP on infarct size and ventricular arrhythmias in anesthetized rats.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11195788     DOI: 10.1023/a:1007119622322

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  20 in total

Review 1.  Lipid activation of protein kinase C.

Authors:  R M Bell; D J Burns
Journal:  J Biol Chem       Date:  1991-03-15       Impact factor: 5.157

2.  Protein kinase C-induced changes in the stoichiometry of ATP binding activate cardiac ATP-sensitive K+ channels. A possible mechanistic link to ischemic preconditioning.

Authors:  P E Light; A A Sabir; B G Allen; M P Walsh; R J French
Journal:  Circ Res       Date:  1996-09       Impact factor: 17.367

Review 3.  The molecular heterogeneity of protein kinase C and its implications for cellular regulation.

Authors:  Y Nishizuka
Journal:  Nature       Date:  1988-08-25       Impact factor: 49.962

4.  Ischemic preconditioning attenuates apoptosis through protein kinase C in rat hearts.

Authors:  T Okamura; T Miura; H Iwamoto; K Shirakawa; S Kawamura; Y Ikeda; M Iwatate; M Matsuzaki
Journal:  Am J Physiol       Date:  1999-11

Review 5.  Studies and perspectives of protein kinase C.

Authors:  Y Nishizuka
Journal:  Science       Date:  1986-07-18       Impact factor: 47.728

6.  Preconditioning protects ischemic rabbit heart by protein kinase C activation.

Authors:  K Ytrehus; Y Liu; J M Downey
Journal:  Am J Physiol       Date:  1994-03

7.  Early phase acute myocardial infarct size quantification: validation of the triphenyl tetrazolium chloride tissue enzyme staining technique.

Authors:  M C Fishbein; S Meerbaum; J Rit; U Lando; K Kanmatsuse; J C Mercier; E Corday; W Ganz
Journal:  Am Heart J       Date:  1981-05       Impact factor: 4.749

8.  Preconditioning of the ischaemic myocardium; involvement of the L-arginine nitric oxide pathway.

Authors:  A Vegh; L Szekeres; J Parratt
Journal:  Br J Pharmacol       Date:  1992-11       Impact factor: 8.739

9.  Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs.

Authors:  G J Gross; J A Auchampach
Journal:  Circ Res       Date:  1992-02       Impact factor: 17.367

10.  Role of bradykinin in myocardial preconditioning.

Authors:  T M Wall; R Sheehy; J C Hartman
Journal:  J Pharmacol Exp Ther       Date:  1994-08       Impact factor: 4.030

View more
  4 in total

1.  The antiarrhythmic effect of centrally administered rilmenidine involves muscarinic receptors, protein kinase C and mitochondrial signalling pathways.

Authors:  M Iwasaki; Y Hayashi; T Kamibayashi; A Yamatodani; T Mashimo
Journal:  Br J Pharmacol       Date:  2008-02-25       Impact factor: 8.739

2.  Hypoxia-regulated activity of PKCepsilon in the lens.

Authors:  Vladimir Akoyev; Satyabrata Das; Snehalata Jena; Laura Grauer; Dolores J Takemoto
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-11-07       Impact factor: 4.799

3.  Antagonism of endogenous nociceptin/orphanin FQ inhibits infarction-associated ventricular arrhythmias via PKC-dependent mechanism in rats.

Authors:  Y Han; Z Guo; L L Wang; L Z Zhang; T P Yao
Journal:  Br J Pharmacol       Date:  2013-10       Impact factor: 8.739

4.  Bradykinin inhibits development of myocardial infarction through B2 receptor signalling by increment of regional blood flow around the ischaemic lesions in rats.

Authors:  Hiroshi Ito; Izumi Hayashi; Tohru Izumi; Masataka Majima
Journal:  Br J Pharmacol       Date:  2003-01       Impact factor: 8.739

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.